Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002370 · ClinicalTrials.gov registry record · NA
Study of Itraconazole in Patients With Advanced HIV Infection
A NA study, sponsored by Janssen.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT00002370: Completed NA study, sponsored by Janssen.
NCT00002370 is a NA study that has completed, run by Janssen. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002370, a NA study, has completed, sponsored by Janssen.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
To demonstrate a dosage regimen for intravenous itraconazole that produces a plasma concentration range comparable to that obtained after currently used oral dosages of itraconazole oral solution; and to obtain preliminary safety data in patients with advanced HIV disease.
Interventions
- DRUG Itraconazole
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Phase | NA |
What the finished NCT00002370 record still lists
NCT00002370 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Itraconazole is the first listed.
NCT00002370 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002370 about?
NCT00002370 is a clinical study titled "Study of Itraconazole in Patients With Advanced HIV Infection". To demonstrate a dosage regimen for intravenous itraconazole that produces a plasma concentration range comparable to that obtained after currently used oral dosages of itraconazole oral solution; and to obtain preliminary safety data in patients with advanced HIV disease.
What is the current status of trial NCT00002370?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants.
What interventions are being tested in trial NCT00002370?
The interventions under investigation include: Itraconazole (DRUG).
Who is sponsoring clinical trial NCT00002370?
This trial is sponsored by Janssen, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002370's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer